Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MIL97
- Development stage
- Phase 1
- Lead developer
- Mabworks Biotech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
MIL97 is a recombinant, humanized, agonistic monoclonal antibody that targets the B-cell surface antigen CD40. By binding to CD40 on various immune cell types, MIL97 acts as an immunostimulatory agent with potential antineoplastic (anti-cancer) activity. The drug was developed by Beijing Mabworks Biotech and has been evaluated in phase 1 clinical trials for the treatment of locally advanced or metastatic solid tumors, including metastatic pancreatic cancer and other solid tumors. Its mechanism involves activating CD40 to stimulate immune responses against tumor cells[1][2][3][6][8].
- Other names
- anti-CD40 agonist monoclonal antibody MIL97anti-CD-40 agonist monoclonal antibody MIL97anti-CD 40 agonist monoclonal antibody MIL97
02
Targets
CD40 (Cluster of differentiation 40 receptor)
Beyond the preview
Go deeper on MIL97.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MIL97.